Erin Campany

Personalchef på MIRUM PHARMACEUTICALS, INC.

59 år

Health Technology

Consumer Services

Profil

Erin Campany is currently Chief People Officer at Mirum Pharmaceuticals, Inc. since 2025.
Former positions include Senior Director-Global Human Resources at Acorda Therapeutics, Inc. from 2013 to 2017, Head-Human Resources at Immune Design Corp.
from 2017 to 2019, and Vice President-Human Resources at Rapt Therapeutics, Inc. Education includes undergraduate studies at San Jose State University.

Aktiva positioner av Erin Campany

Företag	Position	Start
MIRUM PHARMACEUTICALS, INC.	Personalchef	2022-01-01

Alla aktiva positioner av Erin Campany

Tidigare kända positioner av Erin Campany

Företag	Position	Slut
IMMUNE DESIGN CORP	Personalchef	2019-07-01
ACORDA THERAPEUTICS, INC.	Personalchef	2017-09-01
RAPT THERAPEUTICS, INC.	Personalchef	-

Se detaljerna i Erin Campanys erfarenhet

Erin Campanys utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Se detaljerna i Erin Campanys erfarenhet

Relationer

Första gradens relationer

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Se det personliga nätverket

Kopplade företag

Privata företag	5
Acorda Therapeutics, Inc. Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurology therapies	Health Technology
San Jose State University San Jose State University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Immune Design Corp. Immune Design Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical and clinical-stage immunotherapy company	Health Technology
Rapt Therapeutics, Inc. Rapt Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes oral small molecule therapies for patients	Health Technology
Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage therapeutics company developing a novel approach for treating cholestasis liver diseases	Health Technology